Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 829 entries
Sorted by: Best Match Show Resources per page
[Questions and answers on rehabilitation. 2. Definition of the "acceptance of disability"].

Kangogaku zasshi

Gishima H, Kondo M, Shibuya Y, Hoshikawa N.
PMID: 6234418
Kangogaku Zasshi. 1984 May;48(5):577-80.

No abstract available.

Cite
Gishima H, Kondo M, Shibuya Y, et al. [Questions and answers on rehabilitation. 2. Definition of the "acceptance of disability"]. Kangogaku Zasshi. 1984;48(5):577-80
Gishima, H., Kondo, M., Shibuya, Y., & Hoshikawa, N. (1984). [Questions and answers on rehabilitation. 2. Definition of the "acceptance of disability"]. Kangogaku zasshi, 48(5), 577-80.
Gishima, H, et al. "[Questions and answers on rehabilitation. 2. Definition of the "acceptance of disability"]." Kangogaku zasshi vol. 48,5 (1984): 577-80.
Gishima H, Kondo M, Shibuya Y, Hoshikawa N. [Questions and answers on rehabilitation. 2. Definition of the "acceptance of disability"]. Kangogaku Zasshi. 1984 May;48(5):577-80. Japanese. PMID: 6234418.
Copy Download .nbib Format: NLM
Atazanavir nephrotoxicity.

Clinical kidney journal

Hara M, Suganuma A, Yanagisawa N, Imamura A, Hishima T, Ando M.
PMID: 25815168
Clin Kidney J. 2015 Apr;8(2):137-42. doi: 10.1093/ckj/sfv015. Epub 2015 Mar 20.

Atazanavir is commonly used as one of the key drugs in combination antiretroviral therapy for human immunodeficiency virus (HIV). However, atazanavir has the potential to yield its crystalline precipitation in urine and renal interstitial tissues, leading to crystalluria, urolithiasis,...

Cite
Hara M, Suganuma A, Yanagisawa N, et al. Atazanavir nephrotoxicity. Clin Kidney J. 2015;8(2):137-42doi: 10.1093/ckj/sfv015.
Hara, M., Suganuma, A., Yanagisawa, N., Imamura, A., Hishima, T., & Ando, M. (2015). Atazanavir nephrotoxicity. Clinical kidney journal, 8(2), 137-42. https://doi.org/10.1093/ckj/sfv015
Hara, Masaki, et al. "Atazanavir nephrotoxicity." Clinical kidney journal vol. 8,2 (2015): 137-42. doi: https://doi.org/10.1093/ckj/sfv015
Hara M, Suganuma A, Yanagisawa N, Imamura A, Hishima T, Ando M. Atazanavir nephrotoxicity. Clin Kidney J. 2015 Apr;8(2):137-42. doi: 10.1093/ckj/sfv015. Epub 2015 Mar 20. PMID: 25815168; PMCID: PMC4370314.
Copy Download .nbib Format: NLM
A case of fatal intrahepatic cholestasis with primary AL amyloidosis: is early diagnosis possible?.

Clinical journal of gastroenterology

Takao S, Tanaka K, Miyazaki M, Tanaka M, Ohashi T, Kato M, Kotoh K, Aishima S, Takayanagi R.
PMID: 26181836
Clin J Gastroenterol. 2013 Oct;6(5):386-9. doi: 10.1007/s12328-013-0406-x. Epub 2013 Jul 28.

Immunoglobulin light chain-associated (AL) amyloidosis is a multisystemic disorder characterized by extracellular deposition of immunoglobulin light chain produced by a proliferative plasma cell clone. Although the liver is the major organ involved in AL amyloidosis, hepatic involvement is often...

Cite
Takao S, Tanaka K, Miyazaki M, et al. A case of fatal intrahepatic cholestasis with primary AL amyloidosis: is early diagnosis possible?. Clin J Gastroenterol. 2013;6(5):386-9doi: 10.1007/s12328-013-0406-x.
Takao, S., Tanaka, K., Miyazaki, M., Tanaka, M., Ohashi, T., Kato, M., Kotoh, K., Aishima, S., & Takayanagi, R. (2013). A case of fatal intrahepatic cholestasis with primary AL amyloidosis: is early diagnosis possible?. Clinical journal of gastroenterology, 6(5), 386-9. https://doi.org/10.1007/s12328-013-0406-x
Takao, Shinichiro, et al. "A case of fatal intrahepatic cholestasis with primary AL amyloidosis: is early diagnosis possible?." Clinical journal of gastroenterology vol. 6,5 (2013): 386-9. doi: https://doi.org/10.1007/s12328-013-0406-x
Takao S, Tanaka K, Miyazaki M, Tanaka M, Ohashi T, Kato M, Kotoh K, Aishima S, Takayanagi R. A case of fatal intrahepatic cholestasis with primary AL amyloidosis: is early diagnosis possible?. Clin J Gastroenterol. 2013 Oct;6(5):386-9. doi: 10.1007/s12328-013-0406-x. Epub 2013 Jul 28. PMID: 26181836.
Copy Download .nbib Format: NLM
Mixed acinar-endocrine carcinoma of the pancreas treated with S-1.

Clinical journal of gastroenterology

Kanemasa Y, Kamisawa T, Tabata T, Kuruma S, Iwasaki S, Chiba K, Kuwata G, Fujiwara T, Egashira H, Koizumi K, Fujiwara J, Arakawa T, Momma K, Rokutan H, Horiguchi S, Hishima T.
PMID: 26182137
Clin J Gastroenterol. 2013 Dec;6(6):459-64. doi: 10.1007/s12328-013-0416-8. Epub 2013 Sep 05.

The case of a 63-year-old male with a large mass in the pancreatic tail and multiple liver metastases, diagnosed as acinar cell carcinoma of the pancreas with a few scattered endocrine cells by liver biopsy is presented. The S-1...

Cite
Kanemasa Y, Kamisawa T, Tabata T, et al. Mixed acinar-endocrine carcinoma of the pancreas treated with S-1. Clin J Gastroenterol. 2013;6(6):459-64doi: 10.1007/s12328-013-0416-8.
Kanemasa, Y., Kamisawa, T., Tabata, T., Kuruma, S., Iwasaki, S., Chiba, K., Kuwata, G., Fujiwara, T., Egashira, H., Koizumi, K., Fujiwara, J., Arakawa, T., Momma, K., Rokutan, H., Horiguchi, S., & Hishima, T. (2013). Mixed acinar-endocrine carcinoma of the pancreas treated with S-1. Clinical journal of gastroenterology, 6(6), 459-64. https://doi.org/10.1007/s12328-013-0416-8
Kanemasa, Yusuke, et al. "Mixed acinar-endocrine carcinoma of the pancreas treated with S-1." Clinical journal of gastroenterology vol. 6,6 (2013): 459-64. doi: https://doi.org/10.1007/s12328-013-0416-8
Kanemasa Y, Kamisawa T, Tabata T, Kuruma S, Iwasaki S, Chiba K, Kuwata G, Fujiwara T, Egashira H, Koizumi K, Fujiwara J, Arakawa T, Momma K, Rokutan H, Horiguchi S, Hishima T. Mixed acinar-endocrine carcinoma of the pancreas treated with S-1. Clin J Gastroenterol. 2013 Dec;6(6):459-64. doi: 10.1007/s12328-013-0416-8. Epub 2013 Sep 05. PMID: 26182137.
Copy Download .nbib Format: NLM
Longitudinal slit procedure in addition to negative pressure wound therapy for a refractory wound with exposed achilles tendon.

Eplasty

Ohata E, Yuzuriha S, Mishima Y, Matsuo K.
PMID: 25848445
Eplasty. 2015 Mar 18;15:e9. eCollection 2015.

OBJECTIVE: This case report reviews features of negative pressure wound therapy, particularly for the exposed Achilles tendon, and describes an additional effective procedure.METHODS: An 87-year-old man presented with a soft-tissue defect measuring 3×5 cm with the exposed Achilles tendon...

Cite
Ohata E, Yuzuriha S, Mishima Y, et al. Longitudinal slit procedure in addition to negative pressure wound therapy for a refractory wound with exposed achilles tendon. Eplasty. 2015;15:e9
Ohata, E., Yuzuriha, S., Mishima, Y., & Matsuo, K. (2015). Longitudinal slit procedure in addition to negative pressure wound therapy for a refractory wound with exposed achilles tendon. Eplasty, 15e9.
Ohata, Erika, et al. "Longitudinal slit procedure in addition to negative pressure wound therapy for a refractory wound with exposed achilles tendon." Eplasty vol. 15 (2015): e9.
Ohata E, Yuzuriha S, Mishima Y, Matsuo K. Longitudinal slit procedure in addition to negative pressure wound therapy for a refractory wound with exposed achilles tendon. Eplasty. 2015 Mar 18;15:e9. eCollection 2015. PMID: 25848445; PMCID: PMC4370208.
Copy Download .nbib Format: NLM
Plasmon resonance-enhanced circularly polarized luminescence of self-assembled meso-tetrakis(4-sulfonatophenyl)porphyrin-surfactant complexes in interaction with Ag nanoparticles.

Chemical communications (Cambridge, England)

Harada T, Kajiyama N, Ishizaka K, Toyofuku R, Izumi K, Umemura K, Imai Y, Taniguchi N, Mishima K.
PMID: 25111425
Chem Commun (Camb). 2014 Oct 04;50(76):11169-72. doi: 10.1039/c4cc04477k.

The chiroptical properties of an anionic meso-tetrakis(4-sulfonatophenyl)porphyrin (TPPS) complexed with cationic surfactants were enhanced by interaction with silver nanoparticles (AgNPs) in acidic solution. Improvement in chiroptical properties was revealed by circular dichroism (CD) and circularly polarized luminescence (CPL), with...

Cite
Harada T, Kajiyama N, Ishizaka K, et al. Plasmon resonance-enhanced circularly polarized luminescence of self-assembled meso-tetrakis(4-sulfonatophenyl)porphyrin-surfactant complexes in interaction with Ag nanoparticles. Chem Commun (Camb). 2014;50(76):11169-72doi: 10.1039/c4cc04477k.
Harada, T., Kajiyama, N., Ishizaka, K., Toyofuku, R., Izumi, K., Umemura, K., Imai, Y., Taniguchi, N., & Mishima, K. (2014). Plasmon resonance-enhanced circularly polarized luminescence of self-assembled meso-tetrakis(4-sulfonatophenyl)porphyrin-surfactant complexes in interaction with Ag nanoparticles. Chemical communications (Cambridge, England), 50(76), 11169-72. https://doi.org/10.1039/c4cc04477k
Harada, Takunori, et al. "Plasmon resonance-enhanced circularly polarized luminescence of self-assembled meso-tetrakis(4-sulfonatophenyl)porphyrin-surfactant complexes in interaction with Ag nanoparticles." Chemical communications (Cambridge, England) vol. 50,76 (2014): 11169-72. doi: https://doi.org/10.1039/c4cc04477k
Harada T, Kajiyama N, Ishizaka K, Toyofuku R, Izumi K, Umemura K, Imai Y, Taniguchi N, Mishima K. Plasmon resonance-enhanced circularly polarized luminescence of self-assembled meso-tetrakis(4-sulfonatophenyl)porphyrin-surfactant complexes in interaction with Ag nanoparticles. Chem Commun (Camb). 2014 Oct 04;50(76):11169-72. doi: 10.1039/c4cc04477k. PMID: 25111425.
Copy Download .nbib Format: NLM
Erratum to: RUNX1 induces DNA replication independent active DNA demethylation at SPI1 regulatory regions.

BMC molecular biology

Goyal S, Suzuki T, Li JR, Maeda S, Kishima M, Nishimura H, Shimizu Y, Suzuki H.
PMID: 28431504
BMC Mol Biol. 2017 Apr 21;18(1):11. doi: 10.1186/s12867-017-0088-x.

No abstract available.

Cite
Goyal S, Suzuki T, Li JR, et al. Erratum to: RUNX1 induces DNA replication independent active DNA demethylation at SPI1 regulatory regions. BMC Mol Biol. 2017;18(1):11doi: 10.1186/s12867-017-0088-x.
Goyal, S., Suzuki, T., Li, J. R., Maeda, S., Kishima, M., Nishimura, H., Shimizu, Y., & Suzuki, H. (2017). Erratum to: RUNX1 induces DNA replication independent active DNA demethylation at SPI1 regulatory regions. BMC molecular biology, 18(1), 11. https://doi.org/10.1186/s12867-017-0088-x
Goyal, Shubham, et al. "Erratum to: RUNX1 induces DNA replication independent active DNA demethylation at SPI1 regulatory regions." BMC molecular biology vol. 18,1 (2017): 11. doi: https://doi.org/10.1186/s12867-017-0088-x
Goyal S, Suzuki T, Li JR, Maeda S, Kishima M, Nishimura H, Shimizu Y, Suzuki H. Erratum to: RUNX1 induces DNA replication independent active DNA demethylation at SPI1 regulatory regions. BMC Mol Biol. 2017 Apr 21;18(1):11. doi: 10.1186/s12867-017-0088-x. PMID: 28431504; PMCID: PMC5399531.
Copy Download .nbib Format: NLM
Irritable bowel syndrome and inflammatory bowel disease: infectious gastroenteritis-related disorders?.

Clinical journal of gastroenterology

Ishihara S, Aziz M, Oshima N, Mishima Y, Imaoka H, Moriyama I, Kinoshita Y.
PMID: 26191801
Clin J Gastroenterol. 2009 Feb;2(1):9-16. doi: 10.1007/s12328-008-0051-y. Epub 2009 Jan 06.

Infectious gastroenteritis may be one of the important factors in the development of irritable bowel syndrome (IBS), with affected individuals often categorized as having post-infectious IBS (PI-IBS), and is linked to the onset of symptoms in approximately 10-20% of...

Cite
Ishihara S, Aziz M, Oshima N, et al. Irritable bowel syndrome and inflammatory bowel disease: infectious gastroenteritis-related disorders?. Clin J Gastroenterol. 2009;2(1):9-16doi: 10.1007/s12328-008-0051-y.
Ishihara, S., Aziz, M., Oshima, N., Mishima, Y., Imaoka, H., Moriyama, I., & Kinoshita, Y. (2009). Irritable bowel syndrome and inflammatory bowel disease: infectious gastroenteritis-related disorders?. Clinical journal of gastroenterology, 2(1), 9-16. https://doi.org/10.1007/s12328-008-0051-y
Ishihara, Shunji, et al. "Irritable bowel syndrome and inflammatory bowel disease: infectious gastroenteritis-related disorders?." Clinical journal of gastroenterology vol. 2,1 (2009): 9-16. doi: https://doi.org/10.1007/s12328-008-0051-y
Ishihara S, Aziz M, Oshima N, Mishima Y, Imaoka H, Moriyama I, Kinoshita Y. Irritable bowel syndrome and inflammatory bowel disease: infectious gastroenteritis-related disorders?. Clin J Gastroenterol. 2009 Feb;2(1):9-16. doi: 10.1007/s12328-008-0051-y. Epub 2009 Jan 06. PMID: 26191801.
Copy Download .nbib Format: NLM
Progerin, the protein responsible for the Hutchinson-Gilford progeria syndrome, increases the unrepaired DNA damages following exposure to ionizing radiation.

Genes and environment : the official journal of the Japanese Environmental Mutagen Society

Noda A, Mishima S, Hirai Y, Hamasaki K, Landes RD, Mitani H, Haga K, Kiyono T, Nakamura N, Kodama Y.
PMID: 27350809
Genes Environ. 2015 Oct 01;37:13. doi: 10.1186/s41021-015-0018-4. eCollection 2015.

INTRODUCTION: Progerin, the protein responsible for the Hutchinson-Gilford Progeria Syndrome (HGPS), is a partially deleted form of nuclear lamin A, and its expression has been suggested as a cause for dysfunctional nuclear membrane and premature senescence. To examine the...

Cite
Noda A, Mishima S, Hirai Y, et al. Progerin, the protein responsible for the Hutchinson-Gilford progeria syndrome, increases the unrepaired DNA damages following exposure to ionizing radiation. Genes Environ. 2015;37:13doi: 10.1186/s41021-015-0018-4.
Noda, A., Mishima, S., Hirai, Y., Hamasaki, K., Landes, R. D., Mitani, H., Haga, K., Kiyono, T., Nakamura, N., & Kodama, Y. (2015). Progerin, the protein responsible for the Hutchinson-Gilford progeria syndrome, increases the unrepaired DNA damages following exposure to ionizing radiation. Genes and environment : the official journal of the Japanese Environmental Mutagen Society, 3713. https://doi.org/10.1186/s41021-015-0018-4
Noda, Asao, et al. "Progerin, the protein responsible for the Hutchinson-Gilford progeria syndrome, increases the unrepaired DNA damages following exposure to ionizing radiation." Genes and environment : the official journal of the Japanese Environmental Mutagen Society vol. 37 (2015): 13. doi: https://doi.org/10.1186/s41021-015-0018-4
Noda A, Mishima S, Hirai Y, Hamasaki K, Landes RD, Mitani H, Haga K, Kiyono T, Nakamura N, Kodama Y. Progerin, the protein responsible for the Hutchinson-Gilford progeria syndrome, increases the unrepaired DNA damages following exposure to ionizing radiation. Genes Environ. 2015 Oct 01;37:13. doi: 10.1186/s41021-015-0018-4. eCollection 2015. PMID: 27350809; PMCID: PMC4917958.
Copy Download .nbib Format: NLM
A rare case of Barrett's adenocarcinoma including squamous cell carcinoma component.

Clinical journal of gastroenterology

Mishima Y, Amano Y, Yuki T, Kusunoki R, Oka A, Uno G, Ishimura N, Hamaoka M, Ishikawa N, Ishihara S, Kinoshita Y.
PMID: 26190613
Clin J Gastroenterol. 2011 Feb;4(1):5-9. doi: 10.1007/s12328-010-0192-7. Epub 2010 Dec 08.

We present a rare case of Barrett's cancer with a particular histology composed of various differentiated adenocarcinoma (AC) and squamous cell carcinoma (SCC) cells. A 52-year-old man with a long-standing complaint of heartburn visited a medical center for an...

Cite
Mishima Y, Amano Y, Yuki T, et al. A rare case of Barrett's adenocarcinoma including squamous cell carcinoma component. Clin J Gastroenterol. 2010;4(1):5-9doi: 10.1007/s12328-010-0192-7.
Mishima, Y., Amano, Y., Yuki, T., Kusunoki, R., Oka, A., Uno, G., Ishimura, N., Hamaoka, M., Ishikawa, N., Ishihara, S., & Kinoshita, Y. (2011). A rare case of Barrett's adenocarcinoma including squamous cell carcinoma component. Clinical journal of gastroenterology, 4(1), 5-9. https://doi.org/10.1007/s12328-010-0192-7
Mishima, Yoshiyuki, et al. "A rare case of Barrett's adenocarcinoma including squamous cell carcinoma component." Clinical journal of gastroenterology vol. 4,1 (2011): 5-9. doi: https://doi.org/10.1007/s12328-010-0192-7
Mishima Y, Amano Y, Yuki T, Kusunoki R, Oka A, Uno G, Ishimura N, Hamaoka M, Ishikawa N, Ishihara S, Kinoshita Y. A rare case of Barrett's adenocarcinoma including squamous cell carcinoma component. Clin J Gastroenterol. 2011 Feb;4(1):5-9. doi: 10.1007/s12328-010-0192-7. Epub 2010 Dec 08. PMID: 26190613.
Copy Download .nbib Format: NLM
2. The Effect of Combined Therapy, Percutaneous Autologous Concentrated Bone Marrow Grafting and Low-Intensity Pulsed Ultrasound (LIPUS), on the Treatment of Non-Unions.

Journal of orthopaedic trauma

Mishima H, Sugaya H, Yoshioka T, Wada H, Aoto K, Hyodo K, Tomaru Y, Kumagai H, Akaogi H, Ochiai N, Yamazaki M.
PMID: 27441763
J Orthop Trauma. 2016 Aug;30(8):S2. doi: 10.1097/01.bot.0000489987.43355.1d.

We discuss the effect of combined therapy of percutaneous autologous concentrated bone graft and LIPUS on complex non-union treatment. Seventeen of 27 treated patients who had received the therapy at least 1 year before were discussed (10 femurs, 5...

Cite
Mishima H, Sugaya H, Yoshioka T, et al. 2. The Effect of Combined Therapy, Percutaneous Autologous Concentrated Bone Marrow Grafting and Low-Intensity Pulsed Ultrasound (LIPUS), on the Treatment of Non-Unions. J Orthop Trauma. 2016;30(8):S2doi: 10.1097/01.bot.0000489987.43355.1d.
Mishima, H., Sugaya, H., Yoshioka, T., Wada, H., Aoto, K., Hyodo, K., Tomaru, Y., Kumagai, H., Akaogi, H., Ochiai, N., & Yamazaki, M. (2016). 2. The Effect of Combined Therapy, Percutaneous Autologous Concentrated Bone Marrow Grafting and Low-Intensity Pulsed Ultrasound (LIPUS), on the Treatment of Non-Unions. Journal of orthopaedic trauma, 30(8), S2. https://doi.org/10.1097/01.bot.0000489987.43355.1d
Mishima, Hajime, et al. "2. The Effect of Combined Therapy, Percutaneous Autologous Concentrated Bone Marrow Grafting and Low-Intensity Pulsed Ultrasound (LIPUS), on the Treatment of Non-Unions." Journal of orthopaedic trauma vol. 30,8 (2016): S2. doi: https://doi.org/10.1097/01.bot.0000489987.43355.1d
Mishima H, Sugaya H, Yoshioka T, Wada H, Aoto K, Hyodo K, Tomaru Y, Kumagai H, Akaogi H, Ochiai N, Yamazaki M. 2. The Effect of Combined Therapy, Percutaneous Autologous Concentrated Bone Marrow Grafting and Low-Intensity Pulsed Ultrasound (LIPUS), on the Treatment of Non-Unions. J Orthop Trauma. 2016 Aug;30(8):S2. doi: 10.1097/01.bot.0000489987.43355.1d. PMID: 27441763.
Copy Download .nbib Format: NLM
Albumin-bound paclitaxel for the treatment of refractory or relapsed small-cell lung cancer.

Molecular and clinical oncology

Yoshida H, Kim YH, Ozasa H, Nagai H, Sakamori Y, Nakaoku T, Yagi Y, Tsuji T, Nomizo T, Mishima M.
PMID: 27330801
Mol Clin Oncol. 2016 Jul;5(1):213-215. doi: 10.3892/mco.2016.887. Epub 2016 May 06.

Since nanoparticle albumin-bound (nab)-paclitaxel exerts clinically meaningful antitumor effects on various malignancies, including breast, gastric and non-small-cell lung cancer, we hypothesized that treatment with nab-paclitaxel may also be beneficial for patients with small-cell lung cancer (SCLC). We herein evaluated...

Cite
Yoshida H, Kim YH, Ozasa H, et al. Albumin-bound paclitaxel for the treatment of refractory or relapsed small-cell lung cancer. Mol Clin Oncol. 2016;5(1):213-215doi: 10.3892/mco.2016.887.
Yoshida, H., Kim, Y. H., Ozasa, H., Nagai, H., Sakamori, Y., Nakaoku, T., Yagi, Y., Tsuji, T., Nomizo, T., & Mishima, M. (2016). Albumin-bound paclitaxel for the treatment of refractory or relapsed small-cell lung cancer. Molecular and clinical oncology, 5(1), 213-215. https://doi.org/10.3892/mco.2016.887
Yoshida, Hironori, et al. "Albumin-bound paclitaxel for the treatment of refractory or relapsed small-cell lung cancer." Molecular and clinical oncology vol. 5,1 (2016): 213-215. doi: https://doi.org/10.3892/mco.2016.887
Yoshida H, Kim YH, Ozasa H, Nagai H, Sakamori Y, Nakaoku T, Yagi Y, Tsuji T, Nomizo T, Mishima M. Albumin-bound paclitaxel for the treatment of refractory or relapsed small-cell lung cancer. Mol Clin Oncol. 2016 Jul;5(1):213-215. doi: 10.3892/mco.2016.887. Epub 2016 May 06. PMID: 27330801; PMCID: PMC4906929.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 829 entries